GlassScriptPhysician profile
Danny W Shaban
NPI 1992707517
$8,040.19
in general payments reported to CMS, 2019-2025
49 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $751 · 2021: $1,318 · 2022: $1,346 · 2023: $731 · 2024: $2,131 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742 · Travel and Lodging: $1,160 · Education: $16.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.61 |
| Travel and Lodging | $1,159.72 |
| Education | $16.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,273.81 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Medical Device Business Services, INC. | $1,227.26 | 2024 | Harmonic |
| Amgen INC. | $540.33 | 2020-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $538.07 | 2021-2025 | |
| Myovant Sciences INC. | $504.84 | 2021-2022 | |
| Organon LLC | $445.19 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $322.62 | 2019-2024 | Acessa Provu System, Coolseal Generator, Aptima |
| Novo Nordisk INC | $312.66 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $264.69 | 2019-2021 | |
| Astellas Pharma US INC | $203.71 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $200.75 | 2019-2022 | |
| Shield Therapeutics INC | $155.38 | 2022-2024 | Accrufer |
| Ethicon US, LLC | $152.63 | 2020-2024 | Harmonic |
| Coopersurgical, INC. | $142.33 | 2020-2025 | Paragard T 380a, Ally II Ups, Paragard T 380a |
| Pfizer INC. | $139.78 | 2019-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $137.56 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $132.49 | 2023 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $103.37 | 2021 | |
| Currax Pharmaceuticals LLC | $98.42 | 2021-2025 | Contrave, Onzetra Xsail |
| Pacira Pharmaceuticals Incorporated | $98.07 | 2019 | |
| Ardelyx, INC. | $94.96 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $76.15 | 2023-2025 | Zepbound, Mounjaro |
| Millicent US INC | $75.78 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Scynexis, INC. | $71.25 | 2022 | |
| Optumhealth Care Solutions, LLC | $70.05 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Ibsa Pharma INC. | $52.45 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $48.87 | 2019-2021 | |
| Cepheid | $46.42 | 2025 | Genexpert |
| Daiichi Sankyo INC. | $41.91 | 2024 | Injectafer |
| Amag Pharmaceuticals, INC. | $40.47 | 2019 | |
| Teleflex LLC | $39.67 | 2021-2022 | |
| Horizon Therapeutics Plc | $35.75 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $32.34 | 2023 | Vivjoa |
| Galderma Laboratories, L.P. | $32.01 | 2019-2022 | |
| Agile Therapeutics, INC. | $29.16 | 2022-2023 | Twirla |
| Duchesnay USA Incorporated | $26.48 | 2019 | |
| Davol INC. | $25.49 | 2023 | Arista Ah Flexitip |
| Becton, Dickinson and Company | $25.26 | 2025 | Arista |
| Vertical Pharmaceuticals, LLC | $24.00 | 2019 | |
| Coloplast Corp | $22.32 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.37 | 2021 | |
| Medicem INC. | $20.26 | 2021 | |
| Avion Pharmaceuticals | $15.37 | 2021 | |
| Intuitive Surgical, INC. | $14.81 | 2019 | |
| Renovia INC | $13.81 | 2021 | |
| Lupin INC. | $13.20 | 2019 | |
| Meditrina | $12.66 | 2024 | |
| Ferring Pharmaceuticals INC. | $12.49 | 2019 | |
| Minerva Surgical, INC | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Shaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.